Inventor · disambiguated record
Dasa Lipovsek
Also filed as: LIPOVSEK DASA
54 granted patents·26 pending applications·1,271 citations·filing 2000–2025
99Inventor score
Files withBRISTOL MYERS SQUIBB CO58COMPOUND THERAPEUTICS INC5LIPOVSEK DASA5CODON DEVICES2ADNEXUS THERAPEUTICS INC1
Top patents by PatentIndex Score
80 records- 0198US7115396B2Protein scaffolds for antibody mimics and other binding proteinsCOMPOUND THERAPEUTICS INC·Filed 2003·Granted Oct 3, 2006·225 cites·33 claims
- 0298US6818418B1Protein scaffolds for antibody mimics and other binding proteinsCOMPOUND THERAPEUTICS INC·Filed 2000·Granted Nov 16, 2004·584 cites·22 claims
- 0397US9662373B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2015·Granted May 30, 2017·27 cites·31 claims
- 0497US9434778B2Modified FGF-21 polypeptides comprising an internal deletion and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 6, 2016·31 cites·20 claims
- 0597US8420098B2Fibronectin based scaffold domain proteins that bind to PCSK9CAMPHAUSEN RAY·Filed 2011·Granted Apr 16, 2013·86 cites·8 claims
- 0696US9522951B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Dec 20, 2016·18 cites·20 claims
- 0796US9416170B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Aug 16, 2016·16 cites·45 claims
- 0896US8933199B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 13, 2015·36 cites·36 claims
- 0996US8853154B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Oct 7, 2014·35 cites·15 claims
- 1095US10406251B2PD-L1 binding polypeptides for imagingBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 10, 2019·15 cites·35 claims
- 1195US9605039B2Protein scaffolds for antibody mimics and other binding proteinsLIPOVSEK DASA·Filed 2006·Granted Mar 28, 2017·29 cites·6 claims
- 1295US8993265B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Mar 31, 2015·27 cites·11 claims
- 1394US10189883B2Therapeutic uses of modified FGF-21 polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jan 29, 2019·12 cites·20 claims
- 1494US9631004B2Modified FGF-21 polypeptides comprising an internal deletion and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Apr 25, 2017·12 cites·17 claims
- 1593US10604556B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 31, 2020·5 cites·20 claims
- 1693US9765132B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Sep 19, 2017·9 cites·46 claims
- 1793US9493546B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Nov 15, 2016·14 cites·20 claims
- 1892US11434275B2Fast-off rate serum albumin binding fibronectin type III domainsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Sep 6, 2022·3 cites·18 claims
- 1992US9856309B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jan 2, 2018·10 cites·16 claims
- 2091US11173219B2PD-L1 binding polypeptides for imagingBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 16, 2021·4 cites·21 claims
- 2191US10947297B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2017·Granted Mar 16, 2021·5 cites·19 claims
- 2291US10266578B2Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·9 cites·30 claims
- 2390US10442851B2Serum albumin-binding fibronectin type III domainsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 15, 2019·5 cites·12 claims
- 2490US10377806B2Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Aug 13, 2019·6 cites·30 claims
- 2590US9234027B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 12, 2016·10 cites·22 claims
- 2689US11344639B2PET imaging with PD-L1 binding polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted May 31, 2022·4 cites·13 claims
- 2788US11524992B2Glypican-3-binding fibronectin based scaffold moleculesBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Dec 13, 2022·2 cites·12 claims
- 2888US11248031B2Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Feb 15, 2022·4 cites·22 claims
- 2987US11407815B2Stabilized fibronectin based scaffold moleculesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Aug 9, 2022·2 cites·16 claims
- 3087US10766946B2Fast-off rate serum albumin binding fibronectin type III domainsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Sep 8, 2020·4 cites·11 claims
- 3187US10464995B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Nov 5, 2019·2 cites·17 claims
- 3287US10450363B2Stabilized fibronectin based scaffold moleculesBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 22, 2019·3 cites·20 claims
- 3387US2024316161A1Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 3486US11203630B2Serum albumin-binding fibronectin type III domainsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Dec 21, 2021·2 cites·9 claims
- 3586US11060085B2Methods for the selection of binding proteinsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jul 13, 2021·1 cites·21 claims
- 3686US2024239870A1Fibronectin based scaffold domain proteins that bind pcsk9BRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 3785US11408093B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Aug 9, 2022·1 cites·20 claims
- 3884US2023183885A1Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 3983US10406212B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Sep 10, 2019·2 cites·11 claims
- 4082US2022275535A1Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 4181US10584160B2Glypican-3-binding fibronectin based scaffold moleculesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 10, 2020·3 cites·22 claims
- 4280US12247058B2Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Mar 11, 2025·0 cites·21 claims
- 4380US10150962B2Methods for the selection of binding proteinsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Dec 11, 2018·1 cites·2 claims
- 4479US12097242B2Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Sep 24, 2024·0 cites·26 claims
- 4578US12492238B2Glypican-3-binding fibronectin based scaffold moleculesBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Dec 9, 2025·0 cites·6 claims
- 4678US12097241B2Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Sep 24, 2024·0 cites·17 claims
- 4778US11279751B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 22, 2022·0 cites·20 claims
- 4878US10245302B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Apr 2, 2019·1 cites·17 claims
- 4978US9347058B2Methods for the selection of binding proteinsLIPOVSEK DASA·Filed 2012·Granted May 24, 2016·2 cites·12 claims
- 5077US11813315B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 14, 2023·0 cites·20 claims
Showing the top 50 of 80 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Dasa Lipovsek files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →